TFS Capital’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

TFS Capital’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-138,394	Closed	-$1.7M	–	1228
2016 Q2	$1.7M	Buy	138,394 +113,668	+460%	+$1.38M	0.31%	46
2016 Q1	$250K	Buy	+24,726	New	+$290K	0.04%	705
2015 Q4	–	Sell	-82,843	Closed	-$1.37M	–	1111
2015 Q3	$1.37M	Buy	82,843 +48,295	+140%	+$968K	0.13%	250
2015 Q2	$777K	Buy	+34,548	New	+$852K	0.08%	402
2013 Q4	–	Sell	-33,160	Closed	-$508K	–	1890
2013 Q3	$508K	Buy	+33,160	New	+$614K	0.02%	861

Other funds holding OMED

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TFS Capital's OMED Position: Q3 2016 in Review

TFS Capital sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2016, closing a stake of 138,394 shares — an estimated $1.7M sold.

TFS Capital first reported a position in OMED in Q3 2013 and held it in 5 quarters. The position peaked at $1.7M in Q2 2016. 89 funds tracked by Wall St. Rank hold OMED as of Q3 2016.

TFS Capital reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 138,394 OncoMed Pharmaceuticals, Inc. shares in Q3 2016, an estimated $1.7M.
TFS Capital first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 5 quarters.
TFS Capital's OncoMed Pharmaceuticals, Inc. position peaked at $1.7M in Q2 2016.
89 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.